Targets › LLT1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis. Inhibits osteoclast formation. (UniProt, Q9UHP7)
Open in Phaseline: the race on LLT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zumutor Biologics | ZM008 anti-LLT1 antibody | LLT1 | Phase 1 | Non Small Cell Lung Cancer | Dec 2026 |
Non Small Cell Lung Cancer (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.